< 1 minute read
Jan. 17, 2022

Compound 17a: a SGK1 Inhibitor for Osteoarthritis

“compound 17a”

SGK1 kinase inhibitor preclinical activity in osteoarthritis explant model from DFG-out virtual screening, SBDD and MPO Journal of Medicinal Chemistry Sanofi, Frankfurt am Main, DE

drughunter.com
Drug Hunter Team

Kinase inhibitors are increasingly being explored for diseases beyond cancer. While SGK1 has been a cancer target, SGK1 has also been implicated in osteoarthritis pathology, and the Sanofi team developed “compound 17a” to interrogate this. The starting point was identified from ligand-based virtual screening, focusing on the DFG-out [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in